CALC

What one share of CalciMedica holds

Pharmaceutical Preparations

We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates target calcium release-activated calcium (“CRAC”) channels and, if approved, would represent a new class of therapeutics.

CalciMedica’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Profit−$1.33
Capex (buildings and equipment)$0.00
Free cash flow−$1.20
Cash and investments$0.61
Book value$0.18

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2022—−$111.16$0.05−$143.00—−$847.19
2023—−$7.66$0.02−$5.75—$1.42
2024—−$1.22$0.00−$1.88—$1.07
2025—−$1.97$0.00−$1.41—−$0.43

Common questions about CalciMedica

How much does one share of CalciMedica earn?

Over the last 12 months, CalciMedica lost $1.33 for each share.

Does CalciMedica pay a dividend?

CalciMedica didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is CalciMedica’s book value per share?

CalciMedica’s book value is $0.18 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of CalciMedica have?

Each share of CalciMedica has $0.61 of cash and investments, as of June 30, 2026.

What is CalciMedica’s free cash flow per share?

−$1.20 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has CalciMedica bought back shares?

CalciMedica’s share count rose about 18152% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.